NCT01542489 Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos Status COMPLETED Phase N/A
NCT01542476 The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction Status COMPLETED Phase N/A
NCT01542463 Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes Status COMPLETED Phase N/A
NCT01542450 Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes Status COMPLETED Phase PHASE1
NCT01542424 An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus Status COMPLETED Phase N/A
NCT01542060 Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus Status COMPLETED Phase N/A
NCT01541215 Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes Status COMPLETED Phase PHASE3
NCT01538511 Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT01536665 The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes Status COMPLETED Phase PHASE1
NCT01536652 Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes Status COMPLETED Phase N/A
NCT01536639 Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes Status COMPLETED Phase N/A
NCT01536626 Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands Status COMPLETED Phase N/A
NCT01536613 Post Marketing Surveillance Study of Biphasic Insulin Aspart 30 Status COMPLETED Phase N/A
NCT01536600 Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes Status COMPLETED Phase N/A
NCT01536028 Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes Status COMPLETED Phase PHASE1
NCT01530048 Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL) Status COMPLETED Phase PHASE1
NCT01529918 Detecting Diabetes Sooner With a Risk Survey for the Family Doctor:Comparing Internet and Traditional Methods of Communication for Patients and Doctors Status UNKNOWN Phase NA